Literature DB >> 11494115

The protrusive phase and full development of integrin-dependent adhesions in colon epithelial cells require FAK- and ERK-mediated actin spike formation: deregulation in cancer cells.

V G Brunton1, V J Fincham, G W McLean, S J Winder, C Paraskeva, J F Marshall, M C Frame.   

Abstract

Integrins play an important role in tumour progression by influencing cellular responses and matrix-dependent adhesion. However, the regulation of matrix-dependent adhesion assembly in epithelial cells is poorly understood. We have investigated the integrin and signalling requirements of cell-matrix adhesion assembly in colon carcinoma cells after plating on fibronectin. Adhesion assembly in these, and in the adenoma cells from which they were derived, was largely dependent on alpha v beta 6 integrin and required phosphorylation of FAK on tyrosine-397. The rate of fibronectin-induced adhesion assembly and the expression of both alpha v beta 6 integrin and FAK were increased during the adenoma-to-carcinoma transition. The matrix-dependent adhesion assembly process, particularly the final stages of complex protrusion that is required for optimal cell spreading, required the activity of extracellular signal-regulated kinase (ERK). Furthermore, phosphorylated ERK was targeted to newly forming cell--matrix adhesions in the carcinoma cells but not the adenoma cells, and inhibition of FAK--tyrosine-397 phosphorylation or MEK suppressed the appearance of phosphorylated ERK at peripheral sites. In addition, inhibition of MEK--ERK activation blocked the formation of peripheral actin microspikes that were necessary for the protrusive phase of cell-matrix adhesion assembly. Thus, MEK--ERK--dependent peripheral actin re-organization is required for the full development of integrin-induced adhesions and this pathway is stimulated in an in vitro model of colon cancer progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494115      PMCID: PMC1505596          DOI: 10.1038/sj.neo.7900149

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  46 in total

1.  Changes in the expression of alpha v integrins in oral squamous cell carcinomas.

Authors:  J Jones; F M Watt; P M Speight
Journal:  J Oral Pathol Med       Date:  1997-02       Impact factor: 4.253

2.  Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src.

Authors:  V J Fincham; M James; M C Frame; S J Winder
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

3.  Dynamin is required for the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase.

Authors:  O Kranenburg; I Verlaan; W H Moolenaar
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

4.  Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src.

Authors:  D D Schlaepfer; T Hunter
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

5.  Phosphospecific antibodies reveal focal adhesion kinase activation loop phosphorylation in nascent and mature focal adhesions and requirement for the autophosphorylation site.

Authors:  P J Ruest; S Roy; E Shi; R L Mernaugh; S K Hanks
Journal:  Cell Growth Differ       Date:  2000-01

6.  v-Src induces tyrosine phosphorylation of focal adhesion kinase independently of tyrosine 397 and formation of a complex with Src.

Authors:  G W McLean; V J Fincham; M C Frame
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence.

Authors:  A C Williams; S J Harper; C Paraskeva
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

8.  Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta.

Authors:  A M Manning; A C Williams; S M Game; C Paraskeva
Journal:  Oncogene       Date:  1991-08       Impact factor: 9.867

9.  Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization.

Authors:  S K Akiyama; S S Yamada; W T Chen; K M Yamada
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

10.  Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts.

Authors:  T H Lin; A E Aplin; Y Shen; Q Chen; M Schaller; L Romer; I Aukhil; R L Juliano
Journal:  J Cell Biol       Date:  1997-03-24       Impact factor: 10.539

View more
  5 in total

1.  SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling.

Authors:  M A Westhoff; B Serrels; V J Fincham; M C Frame; N O Carragher
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

2.  Protein phosphatase 2A negatively regulates integrin alpha(IIb)beta(3) signaling.

Authors:  Francisca C Gushiken; Vimal Patel; Yan Liu; Subhashree Pradhan; Angela L Bergeron; Yuandong Peng; K Vinod Vijayan
Journal:  J Biol Chem       Date:  2008-03-11       Impact factor: 5.157

3.  Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation.

Authors:  Jin Shi; Minghao Sun; Peter K Vogt
Journal:  Oncotarget       Date:  2010-05

4.  The Epstein-Barr virus encoded LMP1 oncoprotein modulates cell adhesion via regulation of activin A/TGFβ and β1 integrin signalling.

Authors:  Mhairi A Morris; Christopher W Dawson; Louise Laverick; Alexandra M Davis; Joe P R Dudman; Sathuwarman Raveenthiraraj; Zeeshan Ahmad; Lee-Fah Yap; Lawrence S Young
Journal:  Sci Rep       Date:  2016-01-19       Impact factor: 4.379

5.  TGFbeta1 signaling via alphaVbeta6 integrin.

Authors:  Martin P Kracklauer; Christian Schmidt; Guido M Sclabas
Journal:  Mol Cancer       Date:  2003-08-07       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.